肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2013年
5期
326-330
,共5页
多药耐药%乳腺癌耐药蛋白%抑制剂%基因表达
多藥耐藥%乳腺癌耐藥蛋白%抑製劑%基因錶達
다약내약%유선암내약단백%억제제%기인표체
Multi-drug resistance (MDR)%BCRP%ABCG2%Inhibitors%Gene expression
肿瘤细胞的多药耐药严重影响肿瘤化疗的疗效，研究肿瘤细胞耐药相关蛋白的生理功能及其转运药物的机制，寻找高效的多药耐药蛋白抑制剂是提高肿瘤化疗效果的重要途径。乳腺癌耐药蛋白(BCRP/ABCG2)是一种介导乳腺癌细胞耐药的重要蛋白，在乳腺癌细胞多药耐药的形成中起关键作用。本文将就BCRP/ABCG2蛋白的结构特点、生理功能、在多药耐药中的作用及其抑制剂等方面的研究进展作一综述。
腫瘤細胞的多藥耐藥嚴重影響腫瘤化療的療效，研究腫瘤細胞耐藥相關蛋白的生理功能及其轉運藥物的機製，尋找高效的多藥耐藥蛋白抑製劑是提高腫瘤化療效果的重要途徑。乳腺癌耐藥蛋白(BCRP/ABCG2)是一種介導乳腺癌細胞耐藥的重要蛋白，在乳腺癌細胞多藥耐藥的形成中起關鍵作用。本文將就BCRP/ABCG2蛋白的結構特點、生理功能、在多藥耐藥中的作用及其抑製劑等方麵的研究進展作一綜述。
종류세포적다약내약엄중영향종류화료적료효，연구종류세포내약상관단백적생리공능급기전운약물적궤제，심조고효적다약내약단백억제제시제고종류화료효과적중요도경。유선암내약단백(BCRP/ABCG2)시일충개도유선암세포내약적중요단백，재유선암세포다약내약적형성중기관건작용。본문장취BCRP/ABCG2단백적결구특점、생리공능、재다약내약중적작용급기억제제등방면적연구진전작일종술。
Multi-drug resistance (MDR) is the main factor accounting for the failure of cancer chemotherapy. In order to improve the success rate of cancer chemotherapy, it is important to research the function and transport mechanism of multi-drug resistance-associated protein and find high-performance inhibitors of MDR protein. BCRP/ABCG2 is a multi-drug resistance associated protein, which plays a significant role in the process of MDR of breast cancer. In this article we reviewed the research progress on structure characteristics and physiological functions of BCRP/ABCG2 protein, as well as its role in MDR and inhibi-tors.
